Article: Medicago initiates work on Swine Flu strain.

QUEBEC CITY, April 28 /PRNewswire-FirstCall/ -- Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received a genetic sequence of the new strain of influenza A (H1N1) that has recently been identified in USA and Mexico, and has commenced laboratory work with its VLP vaccine technology to produce material for testing. According to the World Health Organization ("WHO"), a genetic analysis shows this new flu strain is a never-before-seen mixture of swine, human and avian viruses and has the potential of ...






Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!